Navigation Links
Study paves way for development of macular degeneration cures
Date:1/30/2008

January 28, 2008 Owings Mills, MD -- A new study of age-related macular degeneration (AMD), a disease that affects more than nine million Americans, will pave the way for the biopharmaceutical industry to develop better treatments and cures, according to the Foundation Fighting Blindness, which partially funded the research.

This is the first time that scientists have been able to create an AMD animal model that closely represents the disease in people, said Stephen Rose, Ph.D., Chief Research Officer, Foundation Fighting Blindness. Though there are some treatments for the wet form of AMD, we still dont have a cure for the condition, and millions of people are still at risk of losing their vision to both the dry and wet forms. This new model will greatly enhance the development of better treatments and potentially a cure.

Researchers at the Cleveland Clinic Lerner College of Medicine used oxidative chemicals to sensitize the immune systems in mice and create AMD . The study is titled Oxidative damage-induced inflammation initiates age-related macular degeneration, and was published in the online edition of the scientific journal Nature Medicine on January 27.

Once developed, therapies for the dry form, or early stage of AMD, could be implemented before vision is lost, which would be a dramatic breakthrough in the treatment of the disease, Rose said.


'/>"/>

Contact: David Harrison
david@harrisoncommunications.net
410-804-1728
Foundation Fighting Blindness
Source:Eurekalert

Page: 1

Related medicine news :

1. Study Challenges New Benchmark for High-Volume Heart Transplant Hospitals
2. Samarion(SM) Announces Formation of Outcome Based Study Team for Industrys Only Enterprise Quality Improvement System
3. Study Finds Both Coated Stents Perform the Same
4. Pancreatic cancer: The smaller the tumor, the better your chances, study shows
5. Study Links Snoring to Chronic Bronchitis
6. Study finds genetic link to human herpes susceptibility
7. Researchers at Peoria Pulmonary Associates to study airway bypass procedure for emphysema
8. New study finds resistant organisms at core of soft contact lens corneal infections
9. Feds fund study of drug that may prevent radiation injury
10. Study examines self-expanding plastic stents in the treatment of benign esophageal conditions
11. Amalgam Fillings Dont Affect Childrens Brain Development, Says Study in ADA Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... 30, 2017 , ... According to the American Society of Plastic Surgeons (ASPS), ... the top 5 most popular minimally-invasive cosmetic procedures in the country. With summer close, ... over the next 8-10 weeks. For anyone considering a hair removal procedure, there are ...
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, a ... “ Preventing Hospital Readmissions Through Discharge Planning ” with noted expert Sue Dill ... This conference discusses strategies to prevent readmissions in light of the most recent ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... women’s professional squash, announced it has enlisted New York City-based sports and entertainment ... will develop and procure sponsorship opportunities for the Professional Squash Association (PSA), which ...
(Date:3/29/2017)... Petersburg, FL (PRWEB) , ... March 30, 2017 , ... ... called the "Spice of Life" or "Wonder Spice", it has been used for thousands ... use in the East," says Heshelow, author of " Turmeric: How to Use it ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... provides insight into the challenges employers face in trying to balance both short-term ... employee benefits programs? Adding to the growing complexity, companies are finding that ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... 2017  Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, ... Phase 2b dose-ranging study of AKCEA-APO(a)-L Rx in ... of the study is to determine the dose level ... a planned Phase 3 cardiovascular outcome study. ... collaboration with Novartis to develop and commercialize drugs to ...
(Date:3/29/2017)... QUEBEC CITY , March 29, 2017 /PRNewswire/ ... Food and Drug Administration (FDA) 510(k) clearance for ... launch of this truly personalized orthopaedic restoration. Bodycad ... clearance for a joint reconstruction implant system. ... designed to optimize personalized restoration of the patient,s ...
(Date:3/29/2017)... 29, 2017 Avelas Biosciences, Inc., a clinical stage oncology-focused ... today announced that Carmine N. Stengone , president and chief ... Needham & Company 16 th Annual Healthcare Conference on Wednesday, ... the Westin Grand Central Hotel in New York City ... ...
Breaking Medicine Technology: